First-of-its-kind technology stack in autoimmune diseases.
Provides unprecedented insights into optimal patient treatment pathway.
ScipherMedicine, a precision immunology company matching each patient with their most effective therapy, has acquired Philadelphia-based data, analytics, and software company CrossBridge to bolster its data and analytics capabilities.
The acquisition gives Scipher new data management and analytics capabilities to enable a more granular and real-time understanding of patients’ treatment pathway. CrossBridge’s SaaS value-based care platform bridges gaps between patients, providers, payers, and improves health outcomes and lowers the cost of care for autoimmune disease patients. The transaction has closed, and terms were not disclosed.
“There is a significant need to better understand how and when to apply various therapeutic and diagnostic interventions to improve the treatment pathway for patients,” said Scipher’s Chief Executive Officer Alif Saleh. “To date, we have not had a platform combining critical patient molecular, clinical and claims data as autoimmune diseases, including rheumatoid arthritis.
“The addition of CrossBridge will accelerate our growth and advance our mission to match each patient with their most effective therapy while creating seamless EMR integration and efficiencies for healthcare systems and payers,” added Saleh. “The acquisition allows us to collect and map clinical data and outcomes over time to better track the evolution of patient health and the value of healthcare interventions including blood-based therapy selection tests such as PrismRA.”
PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual’s molecular signature, helping identify who is unlikely to adequately respond to TNFI therapy, the world’s largest selling drug class, so non-responders can be prescribed alternative effective therapy and avoid unnecessary dose escalations or drug cycles.
“We are excited to contribute to the vital innovation that Scipher has pioneered for millions of patients, and we are glad to see our data analytics capabilities used to deliver value to patients, providers and payers,” said CrossBridge Founder Bill Conlan.
“This acquisition is an exciting milestone and a key part of our growth strategy,” Saleh said. “One of our goals is to disrupt systemic inefficiencies in healthcare, and CrossBridge will help us realize that vision.”
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
